{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["29(12)"],"submitter":["Lucchini R"],"pubmed_abstract":["<h4>Background</h4>The aim of this study was to investigate the feasibility of ultrahypofractionated radiotherapy to the prostate bed in patients with biochemical and/or clinical relapse following radical prostatectomy who were enrolled in the prospective, observational, multicentric POPART trial (NCT04831970).<h4>Methods</h4>Patients with post-radical prostatectomy PSA levels of ≥0.1-2.0 ng/mL and/or local relapse at PSMA PET/CT or multiparametric MRI were treated with Linac-based SBRT on the prostate bed up to a total dose of 32.5 Gy in five fractions every other day (EQD2<sub>1.5</sub> = 74.2 Gy). Maximum acute toxicity was assessed using the Common Terminology Criteria for Adverse Events version 5 scale. International Consultation on Incontinence Questionnaire-Short Form (ICIQ-SF) and "],"journal":["Current oncology (Toronto, Ont.)"],"pagination":["9349-9356"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC9776836"],"repository":["biostudies-literature"],"pubmed_title":["Acute Toxicity and Quality of Life in a Post-Prostatectomy Ablative Radiation Therapy (POPART) Multicentric Trial."],"pmcid":["PMC9776836"],"pubmed_authors":["Faccenda V","Andreoli S","Cazzaniga LF","Vukcaj S","Panizza D","Scorsetti M","Arcangeli S","Baldaccini D","Purrello G","Lucchini R","Poli GL","Tomatis S","Franzese C","Lo Faro L"],"additional_accession":[]},"is_claimable":false,"name":"Acute Toxicity and Quality of Life in a Post-Prostatectomy Ablative Radiation Therapy (POPART) Multicentric Trial.","description":"<h4>Background</h4>The aim of this study was to investigate the feasibility of ultrahypofractionated radiotherapy to the prostate bed in patients with biochemical and/or clinical relapse following radical prostatectomy who were enrolled in the prospective, observational, multicentric POPART trial (NCT04831970).<h4>Methods</h4>Patients with post-radical prostatectomy PSA levels of ≥0.1-2.0 ng/mL and/or local relapse at PSMA PET/CT or multiparametric MRI were treated with Linac-based SBRT on the prostate bed up to a total dose of 32.5 Gy in five fractions every other day (EQD2<sub>1.5</sub> = 74.2 Gy). Maximum acute toxicity was assessed using the Common Terminology Criteria for Adverse Events version 5 scale. International Consultation on Incontinence Questionnaire-Short Form (ICIQ-SF) and ","dates":{"release":"2022-01-01T00:00:00Z","publication":"2022 Nov","modification":"2025-04-05T14:54:49.763Z","creation":"2025-04-05T14:54:49.763Z"},"accession":"S-EPMC9776836","cross_references":{"pubmed":["36547147"],"doi":["10.3390/curroncol29120733"]}}